Patient outcomes in longitudinal observational studies (POLOS) of rheumatoid arthritis: Determining the OMERACT core domain set.

Autor: Benavent D; Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: d_benavent@hotmail.com., Carmona L; Instituto de Salud Musculoesquelética, Madrid, Spain., Lopez-Olivo MA; Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Texas, USA., Hill CL; Discipline of Medicine, University of Adelaide; Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia., Westrich-Robertson T; International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), St. Louis, MO, USA., Goel N; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Strand V; Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA., Shea B; Ottawa Hospital Research Institute, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada., Grosskleg S; Secretariat, OMERACT, University of Ottawa, Ottawa, Ontario, Canada., Leong A; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada., Hofstetter C; Patient Research Partner, Canada., Bingham C; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore MD, USA., Meyer D; Dartmouth Medical School, Hanover, NH, USA., Constien D; Patient Research Partner, USA., Berthelsen DB; Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Denmark; Department of Rehabilitation, Municipality of Guldborgsund, Nykoebing F, Denmark., Schultz G; Patient Research Partner, USA., de Groot I; Patient Research Partner, the Netherlands., Weiner J; Patient Research Partner, USA., Mather K; Patient Research Partner, Canada., de Wit M; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health., Böhm P; Patient Research Partner, Germany., Cembalo SM; Patient Research Partner, France., Tugwell P; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada., Bruera S; Department of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, USA., Suarez-Almazor ME; Section of Rheumatology and Clinical Immunology, University of Texas MD Anderson Cancer Center, Texas, USA.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2024 Feb; Vol. 64, pp. 152343. Date of Electronic Publication: 2023 Dec 13.
DOI: 10.1016/j.semarthrit.2023.152343
Abstrakt: Objective: To define and select rheumatoid arthritis (RA)-specific core domain set for Longitudinal Observational Studies (LOS) within the Outcome Measures in Rheumatology (OMERACT) framework.
Methods: A three-round online Delphi exercise, including patient research partners (PRPs) and other community partners in healthcare, was conducted. Domains scored 7-9 (i.e., critically important to include) by ≥ 70 % of participants in both groups were included. Items were consolidated in a subsequent dedicated meeting.
Results: Nineteen domains scored ≥ 70 % consensus in both groups. The focus group refined these into a list of twelve domains.
Conclusion: The achieved consensus will inform the next steps of developing the core domain set for LOS in RA.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DB: Speakers bureau: Janssen, UCB, MSD, Abbvie, Galapagos, Lilly. Research Grant: Novartis; LC: Participation on a Data Safety Monitoring Board or Advisory Board: Lilly, Hospital Clínico San Carlos. EULAR Chair of Advocacy; MALO: Grants: National Cancer Institute, Rheumatology Research Foundation, Duncan Family Institute for Cancer Prevention and Risk Assessment. Consulting fees: American Cancer Society; MdW: Speakers bureau: UCB. Convenor EULAR study group for collaborative research; VS: Founding member of the executive committee of OMERACT [1992 – present]; DBB: Support for attending meetings: Erna Hamilton Foundation. Grants: PhD Scholarships from Odense University Hospital and from the Faculty of Health Sciences; Peter Böhm: Support for attending meetings and/or travel: EULAR, FOREUM. MSA: Consulting fees: Pfizer, Eli Lilly, Syneos Health and Celgene. The rest of the authors declare no conflicts of interest.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: